CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death - Archive ouverte HAL Access content directly
Journal Articles iScience Year : 2021

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

(1, 2, 3) , (1, 2) , (4, 5, 1) , (4, 5, 1) , (1, 2) , (1, 2) , (1, 2) , (6) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (4, 5) , (4, 5) , (7, 8, 9) , (7, 8, 9) , (7, 8, 9) , (7) , (7) , (7, 9) , (1, 2, 6) , (1, 2) , (1, 5, 4, 10)
1
2
3
4
5
6
7
8
9
10

Abstract

The identification of patients with coronavirus disease 2019 and high risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in intensive care unit (ICU) than non-ICU patients (P < 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.

Keywords

Dates and versions

hal-03477973 , version 1 (13-12-2021)

Identifiers

Cite

Yves Lévy, Aurélie Wiedemann, Boris P. Hejblum, Mélany Durand, Cécile Lefebvre, et al.. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. iScience, 2021, 24 (7), pp.102711. ⟨10.1016/j.isci.2021.102711⟩. ⟨hal-03477973⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More